SCHEMBL867170

SCHEMBL867170

Cc1cc(C(=O)O)cc(Cl)c1N

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TTR P02766 3/20 0.52
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.45
TPMT P51580 3/20 0.45
PLAU P00749 1/20 0.43
SRD5A2 P31213 1/20 0.40
GRM1 Q13255 2/20 0.40
HSD11B1 P28845 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HCAR1 Q9BXC0 2/20 0.39
TNKS2 Q9H2K2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
DAO P14920 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285092 0.85 TTR (0.62) TTRTSHRTPMTPLAUSRD5A2
SCHEMBL901041 0.85 TPMT (0.54) TTRKDM4ETSHRTPMTGRM1
SCHEMBL3854731 0.84 CA5A (0.40) KDM4ETSHRHSD11B1CYP1A2KMT2A
Hydrochloric Acid SCHEMBL11627207 0.83 TTR (0.60) TTRTSHRTPMTPLAUSRD5A2
SCHEMBL23973915 0.79 ALDH1A1 (0.49) KDM4EPLAUHSD11B1ALDH1A1
SCHEMBL8060962 0.79 CA12 (0.46) KDM4EMEN1KMT2ATDP1ALDH1A1
SCHEMBL1759305 0.79 TTR (0.56) TTRKDM4ETSHRTPMTPLAU
SCHEMBL10300670 0.79 TTR (0.56) TTRTSHRTPMTPLAUSRD5A2
SCHEMBL1509519 0.79 KDM4E (0.48) TTRKDM4ETSHRTPMTGRM1
SCHEMBL983707 0.78 TTR (0.72) TTRKDM4ETSHRTPMTPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799791-B1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2016-01-13 EP claimed
US-7687118-B2 Photocrosslinkable materials ROLIC AG (CH) 2010-03-30 US claimed
US-20080069968-A1 Photocrosslinkable Materials ROLIC AG (CH) 2008-03-20 US claimed
US-20070191488-A1 Method for the treatment of a ubiquitin conjugating disorder BANERJEE AMIT 2007-08-16 US claimed
EP-1799791-A1 PHOTOCROSSLINKABLE MATERIALS Rolic AG (CH) 2007-06-27 EP claimed
EP-1778011-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS Hygeia Biological Systems (US) 2007-05-02 EP claimed
WO-2006039824-A1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2006-04-20 WO claimed
WO-2006020681-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS HYGEIA BIOLOGICAL SYSTEMS (US) 2006-02-23 WO claimed
US-20060035890-A1 Compounds and methods for the treatment of ubiquitin conjugating disorders AMIT BANERJEE 2006-02-16 US claimed
US-20250180952-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2025-06-05 US disclosed
CN-115803322-B SARS-COV-2 inhibitors with covalent modifications for treatment of coronavirus infection 英矽智能科技知识产权有限公司 2025-05-13 CN disclosed
EP-4493638-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2025-01-22 EP disclosed
CN-118871548-A Photoalignment materials 罗利克技术有限公司 2024-10-29 CN disclosed
CN-118027412-A Photo-alignment material 罗利克技术有限公司 2024-05-14 CN disclosed
US-5665739-A CARDIOVASCULAR DISORDERS HOECHST AKTIENGESELLSCHAFT (DE) 1997-09-09 US disclosed
EP-0603650-B1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AG (DE) 1997-04-02 EP disclosed
EP-0602523-B1 Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them HOECHST AG (DE) 1996-12-11 EP disclosed
US-5516805-A 3,5-substituted aminobenzoylguanidines, their use as a medicament or diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-14 US disclosed
EP-0603650-A1 3,5-Substituted amino benzoylguanidines, process for their preparation, their use as medicine or diagnostic agent, as well as a medicine containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-29 EP disclosed
EP-0602523-A1 Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080069968-A1 Photocrosslinkable Materials PARG, VSIR, IGLV6-57 TTR 1578/4885KDM4E 844/4885TSHR 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.